SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
4.930
-0.020 (-0.40%)
At close: May 1, 2026, 4:00 PM EDT
4.902
-0.028 (-0.57%)
After-hours: May 1, 2026, 4:36 PM EDT
SELLAS Life Sciences Group Earnings Call Transcripts
Fiscal Year 2025
-
Late-stage programs GPS and SLS009 show strong clinical promise in AML, with GPS nearing pivotal REGAL trial results and SLS009 advancing to frontline studies. Financial position is robust, supporting key milestones and commercialization planning, with regulatory designations and FDA engagement accelerating development.
Fiscal Year 2024
-
The phase III REGAL study for GPS in AML has reached its interim analysis trigger, with the IDMC set to review efficacy, futility, and safety in January. Outcomes may include trial continuation, modification, or early stopping for efficacy or futility.